Analysis of tumor RNA-seq data showed that T cell inflamed signature was significantly enriched upon EGFR-TKI treatment in patients with prolonged response (TTP > 12 months) but not in patients with short duration of response (TTP of 0 – 8.6 month) (Figure 1E). The gene discussed is EGFR; the disease is neoplasm.